Is MNPR or MRK more undervalued in 2026?

CirclFi compares Monopar Therapeutics Inc. (MNPR) and Merck & Company, Inc. (MRK) using 13 institutional-grade valuation models. MNPR has a Quality of Company score of 4.3/10 while MRK scores 9.8/10.

Which is a better buy — MNPR or MRK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MNPR and MRK valuations compare?

MNPR at $65.04 and MRK at $118.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MNPR vs MRK Valuation Comparison 2026 — Intrinsic Value Analysis

MNPR

Pharmaceutical Preparations

Monopar Therapeutics Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$65.04

Last close

Models

8/13

Active

MRK

Pharmaceutical Preparations

Merck & Company, Inc.

Quality

9.8

out of 10

Value Trap

—

Price

$118.72

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	MNPR Fair Value	MNPR Upside	MRK Fair Value	MRK Upside
Bayesian DCF	Intrinsic	$20.61	-68.3%	$67.39	-43.2%
Earnings Power Value	Intrinsic	—	—	$17.85	-85.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$6.22	-90.4%	$46.33	-61.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MNPR vs MRK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MNPR vs MRK — Which Stock Is More Undervalued?

MRK scores higher with a 9.8/10 quality rating vs MNPR's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Monopar Therapeutics Inc. (MNPR) and Merck & Company, Inc. (MRK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MNPR currently trades at $65.04 with a QOC of 4.3/10, while MRK trades at $118.72 with a QOC of 9.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).